Nikolas Herold

List of Publications by Year
in descending order

30 papers	805 citations	623734 14 h-index	526287 27 g-index
30 all docs	30 docs citations	30 times ranked	1275 citing authors

#	Article	IF	Citations
1	Response to mitogenâ€activated protein kinase inhibition of neurodegeneration in Langerhans cell histiocytosis monitored by cerebrospinal fluid neurofilament light as a biomarker: a pilot study. British Journal of Haematology, 2022, 196, 248-254.	2.5	9
2	Clinical and biological impact of SAMHD1 expression in mantle cell lymphoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 655-666.	2.8	1
3	Sting Is Commonly and Differentially Expressed in T- and Nk-Cell but Not B-Cell Non-Hodgkin Lymphomas. Cancers, 2022, 14, 1186.	3.7	4
4	A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastomaâ€"LuDO-N. Frontiers in Pediatrics, 2022, 10, 836230.	1.9	5
5	Pharmacological strategies to overcome treatment resistance in acute myeloid leukemia: increasing leukemic drug exposure by targeting the resistance factor SAMHD1 and the toxicity factor Top2Î². Expert Opinion on Drug Discovery, 2021, 16, 7-11.	5.0	6
6	Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines. International Journal of Oncology, 2021, 58, 211-225.	3.3	16
7	Expression of the novel tumour suppressor sterile alpha motif and HD domainâ€containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma. British Journal of Haematology, 2021, 193, 488-496.	2.5	12
8	Heterogeneities in Cell Cycle Checkpoint Activation Following Doxorubicin Treatment Reveal Targetable Vulnerabilities in TP53 Mutated Ultra High-Risk Neuroblastoma Cell Lines. International Journal of Molecular Sciences, 2021, 22, 3664.	4.1	4
9	Evidence for SAMHD1 Tumor Suppressor Functions in Acute Myeloid Leukemia. Acta Haematologica, 2020, 143, 7-8.	1.4	1
10	Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. International Journal of Molecular Sciences, 2020, 21, 6885.	4.1	156
11	Ribonucleotide reductase inhibitors suppress <scp>SAMHD</scp> 1 araâ€•<scp>CTP</scp> ase activity enhancing cytarabine efficacy. EMBO Molecular Medicine, 2020, 12, e10419.	6.9	35
12	Abstract P3-08-07: Expression of the novel tumor suppressor gene SAMHD1 correlates with favourable clinical outcome in basal-like (BL) early breast cancer. , 2020, , .		0
13	Overexpression of the Interferon-Inducible Isoform 4 of NCOA7 Dissects the Entry Route of Enveloped Viruses and Demonstrates that HIV Enters Cells via Fusion at the Plasma Membrane. Viruses, 2019, 11, 121.	3.3	1
14	Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens. Blood Cancer Journal, 2018, 8, 98.	6.2	28
15	Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and Metabolism. Cancers, 2018, 10, 240.	3.7	80
16	The Novel Tumor Suppressor SAMHD1 Is Differentially Expressed and Partly Regulated By MYC in Peripheral T-Cell Lymphomas (PTCL). Blood, 2018, 132, 4130-4130.	1.4	1
17	Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nature Medicine, 2017, 23, 256-263.	30.7	102
18	SAMHD1 is a barrier to antimetabolite-based cancer therapies. Molecular and Cellular Oncology, 2017, 4, e1287554.	0.7	13

#	Article	IF	Citations
19	SAMHD1 protects cancer cells from various nucleoside-based antimetabolites. Cell Cycle, 2017, 16, 1029-1038.	2.6	56
20	With me or against me: Tumor suppressor and drug resistance activities of SAMHD1. Experimental Hematology, 2017, 52, 32-39.	0.4	43
21	Effects of Inner Nuclear Membrane Proteins SUN1/UNC-84A and SUN2/UNC-84B on the Early Steps of HIV-1 Infection. Journal of Virology, 2017, 91, .	3.4	18
22	Improved Local Control by Extensive Surgery in High-Risk Neuroblastoma May Be Dependent on Adjuvant Radiotherapy. Journal of Clinical Oncology, 2017, 35, 1965-1966.	1.6	7
23	The Early Bird Catches the Worm - Can Evolution Teach us Lessons in Fighting HIV?. Current HIV Research, 2016, 14, 183-210.	0.5	5
24	Complex Interplay between HIV-1 Capsid and MX2-Independent Alpha Interferon-Induced Antiviral Factors. Journal of Virology, 2016, 90, 7469-7480.	3.4	40
25	A small leak will sink a great ship: HIVâ€“host interactions. , 2016, , 25-42.		0
26	Reply to â€œCan HIV-1 Entry Sites Be Deduced by Comparing Bulk Endocytosis to Functional Readouts for Viral Fusion?â€• Journal of Virology, 2015, 89, 2986-2987.	3.4	11
27	Quantitation of endogenous nucleoside triphosphates and nucleosides in human cells by liquid chromatography tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2015, 407, 3693-3704.	3.7	32
28	The Nucleocapsid Domain of Gag Is Dispensable for Actin Incorporation into HIV-1 and for Association of Viral Budding Sites with Cortical F-Actin. Journal of Virology, 2014, 88, 7893-7903.	3.4	23
29	HIV-1 Entry in SupT1-R5, CEM-ss, and Primary CD4⁺T Cells Occurs at the Plasma Membrane and Does Not Require Endocytosis. Journal of Virology, 2014, 88, 13956-13970.	3.4	58
30	A quantitative measure for alterations in the actin cytoskeleton investigated with automated highâ€throughput microscopy. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2010, 77A, 52-63.	1.5	38